Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 2
2016 1
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.
Gao SP, Chang Q, Mao N, Daly LA, Vogel R, Chan T, Liu SH, Bournazou E, Schori E, Zhang H, Brewer MR, Pao W, Morris L, Ladanyi M, Arcila M, Manova-Todorova K, de Stanchina E, Norton L, Levine RL, Altan-Bonnet G, Solit D, Zinda M, Huszar D, Lyden D, Bromberg JF. Gao SP, et al. Among authors: bournazou e. Sci Signal. 2016 Mar 29;9(421):ra33. doi: 10.1126/scisignal.aac8460. Sci Signal. 2016. PMID: 27025877 Free PMC article.
Antitumorigenic potential of STAT3 alternative splicing modulation.
Zammarchi F, de Stanchina E, Bournazou E, Supakorndej T, Martires K, Riedel E, Corben AD, Bromberg JF, Cartegni L. Zammarchi F, et al. Among authors: bournazou e. Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17779-84. doi: 10.1073/pnas.1108482108. Epub 2011 Oct 17. Proc Natl Acad Sci U S A. 2011. PMID: 22006329 Free PMC article.
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis.
Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, Cotari J, Alpaugh ML, de Stanchina E, Manova K, Li M, Bonafe M, Ceccarelli C, Taffurelli M, Santini D, Altan-Bonnet G, Kaplan R, Norton L, Nishimoto N, Huszar D, Lyden D, Bromberg J. Chang Q, et al. Among authors: bournazou e. Neoplasia. 2013 Jul;15(7):848-62. doi: 10.1593/neo.13706. Neoplasia. 2013. PMID: 23814496 Free PMC article.
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.
Dickinson M, Briones J, Herrera AF, González-Barca E, Ghosh N, Cordoba R, Rutherford SC, Bournazou E, Labriola-Tompkins E, Franjkovic I, Chesne E, Brouwer-Visser J, Lechner K, Brennan B, Nüesch E, DeMario M, Rüttinger D, Kornacker M, Hutchings M. Dickinson M, et al. Among authors: bournazou e. Blood Adv. 2021 Nov 23;5(22):4762-4770. doi: 10.1182/bloodadvances.2021004619. Blood Adv. 2021. PMID: 34581757 Free PMC article. Clinical Trial.